

2022 Antibiogram (January-December)

Gram Negative Organisms																	
Legend:		Amikacin	Ampicillin	Amp/sulbactam	Cefazolin ²	Cefoxitin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem	Levofloxacin	Pip/Tazobactam	Tobramycin	Trimethoprim/ sulfa	Nitrofurantoin Urinary Tract Infections only	Cefepime ³
• Susceptible Reported as %																	
• (Maximum # strains tested)																	
↑ > 5% increase in Susceptibility from Previous Year																	
↓ > 5% decrease in Susceptibility from Previous Year																	
<i>Escherichia coli</i>	(2023)	100	63	69	93 ²	93	98	95	89	94	100	88	98	95	86	97	-
<i>Enterobacter species</i>	(169)	100	-	-	0	0	80↓	79↓	98	100	99	98	78↓	100	95	32↑	-
<i>Klebsiella species</i>	(467)	100	0	81	92 ²	95	96	93	94	98	100	94	97	96	91	37	-
<i>Proteus species</i>	(198)	100	84↑	90	99 ²	96	99	99	90	98	100	90	99	98	90	0	-
<i>Pseudomonas aeruginosa</i>	(185)	100	-	-	-	-	97↑	-	97	98	99	96↑	93	99	-	-	94

Gram Positive Organisms																	
Legend:		Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin ⁴	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/ sulfa	Vancomycin	Nitrofurantoin Urinary Tract Infections only
• Susceptible Reported as %																	
• (Maximum # strains tested)																	
↑ > 5% increase in Susceptibility from Previous Year																	
↓ > 5% decrease in Susceptibility from Previous Year																	
Methicillin Susceptible <i>Staphylococcus aureus</i>	(486)	-	-	-	83	67	100	93	100	100	0	-	-	92	98	100	35/35
Methicillin Resistant <i>Staphylococcus aureus</i>	(274)	-	-	-	73	9	100	53	100	0	0	-	-	93	77↓	100	18/18
<i>Staphylococcus coagulase negative</i>	(253)	-	-	-	80↑	55↑	97↑	79↑	100	62↑	0	-	-	87	83↑	100	99
<i>Enterococcus faecalis</i>	(214)	100	-	-	-	-	-	77	100	-	100	-	-	-	-	95	100
<i>Enterococcus faecium</i> ⁵	(48)	5/48	-	-	-	-	-	4/48	48/48	-	5/48	-	-	-	-	19/48	3/36
<i>Streptococcus pneumoniae</i> ⁵	(46)	-	46/46	42/46	40/46	33/46	-	46/46	45/45	-	-	46/46	34/46	40/46	-	45/45	-
<i>Streptococcus agalactiae</i> (Group B) ⁵	(20)	20/20	-	-	10/20	9/20	-	20/20	20/20	-	20/20	-	-	-	-	20/20	-

1. Data includes Springfield Hospital population.
2. Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
3. Cefepime tested by manual method on *Pseudomonas aeruginosa*.
4. Oxacillin is tested as a surrogate for methicillin and nafcillin
5. Reported as actual number of isolates susceptible. Trend assessment not provided due to low number of isolates.